Tags

Type your tag names separated by a space and hit enter

A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
Clin Ther. 2014 Dec 01; 36(12):2082-2093.CT

Abstract

PURPOSE

Sucroferric oxyhydroxide is the newest phosphate binder to receive US Food and Drug Administration approval for patients on dialysis. The purpose of this review is to critically evaluate the studies that have been conducted with this medication and determine where it may fit in the clinician's overall treatment plan for hyperphosphatemia in patients with chronic kidney disease.

METHODS

Literature searches were performed in the PubMed database and www.ClinicalTrials.gov using the search terms sucroferric oxyhydroxide, and PA21 phosphate binder. Limits were set to include only clinical trials performed in human subjects.

FINDINGS

Four completed clinical trials and 3 ongoing studies were identified. Completed clinical trials included Phase I, Phase II, and Phase III studies that all demonstrated the ability of sucroferric oxyhydroxide to lower serum phosphorus concentrations. One study compared sucroferric oxyhydroxide with sevelamer and reported no statistically significant difference in serum phosphorus-lowering ability. The ongoing trials are evaluating sucroferric oxyhydroxide for long term use, in peritoneal dialysis patients, and compared with calcium-based phosphate binders.

IMPLICATIONS

Sucroferric oxyhydroxide is an effective phosphate binder for chronic kidney disease patients receiving hemodialysis and may offer an advantage in terms of pill burden. Gastrointestinal side effects are similar to those of current phosphate binders. Advantages of other phosphate binders (ie, the lipid- and uric acid-lowering abilities of sevelamer) may outweigh the pill burden benefits of sucroferric oxyhydroxide.

Authors+Show Affiliations

Purdue University College of Pharmacy, West Lafayette, Indiana.Indiana University Health Arnett Nephrology, Lafayette, Indiana.Indiana University Health Arnett Nephrology, Lafayette, Indiana.Purdue University College of Pharmacy, West Lafayette, Indiana. Electronic address: sheplerb@purdue.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

25450474

Citation

Bousher, Ava, et al. "A Review of Sucroferric Oxyhydroxide for the Treatment of Hyperphosphatemia in Patients Receiving Dialysis." Clinical Therapeutics, vol. 36, no. 12, 2014, pp. 2082-2093.
Bousher A, Al-Makki A, Sutton J, et al. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis. Clin Ther. 2014;36(12):2082-2093.
Bousher, A., Al-Makki, A., Sutton, J., & Shepler, B. (2014). A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis. Clinical Therapeutics, 36(12), 2082-2093. https://doi.org/10.1016/j.clinthera.2014.09.021
Bousher A, et al. A Review of Sucroferric Oxyhydroxide for the Treatment of Hyperphosphatemia in Patients Receiving Dialysis. Clin Ther. 2014 Dec 1;36(12):2082-2093. PubMed PMID: 25450474.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis. AU - Bousher,Ava, AU - Al-Makki,Akram, AU - Sutton,James, AU - Shepler,Brian, Y1 - 2014/10/29/ PY - 2014/06/20/received PY - 2014/08/19/revised PY - 2014/09/29/accepted PY - 2014/12/3/entrez PY - 2014/12/3/pubmed PY - 2016/3/24/medline KW - PA 21 KW - Velphoro KW - sucroferric oxyhydroxide SP - 2082 EP - 2093 JF - Clinical therapeutics JO - Clin Ther VL - 36 IS - 12 N2 - PURPOSE: Sucroferric oxyhydroxide is the newest phosphate binder to receive US Food and Drug Administration approval for patients on dialysis. The purpose of this review is to critically evaluate the studies that have been conducted with this medication and determine where it may fit in the clinician's overall treatment plan for hyperphosphatemia in patients with chronic kidney disease. METHODS: Literature searches were performed in the PubMed database and www.ClinicalTrials.gov using the search terms sucroferric oxyhydroxide, and PA21 phosphate binder. Limits were set to include only clinical trials performed in human subjects. FINDINGS: Four completed clinical trials and 3 ongoing studies were identified. Completed clinical trials included Phase I, Phase II, and Phase III studies that all demonstrated the ability of sucroferric oxyhydroxide to lower serum phosphorus concentrations. One study compared sucroferric oxyhydroxide with sevelamer and reported no statistically significant difference in serum phosphorus-lowering ability. The ongoing trials are evaluating sucroferric oxyhydroxide for long term use, in peritoneal dialysis patients, and compared with calcium-based phosphate binders. IMPLICATIONS: Sucroferric oxyhydroxide is an effective phosphate binder for chronic kidney disease patients receiving hemodialysis and may offer an advantage in terms of pill burden. Gastrointestinal side effects are similar to those of current phosphate binders. Advantages of other phosphate binders (ie, the lipid- and uric acid-lowering abilities of sevelamer) may outweigh the pill burden benefits of sucroferric oxyhydroxide. SN - 1879-114X UR - https://www.unboundmedicine.com/medline/citation/25450474/A_review_of_sucroferric_oxyhydroxide_for_the_treatment_of_hyperphosphatemia_in_patients_receiving_dialysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0149-2918(14)00613-4 DB - PRIME DP - Unbound Medicine ER -